Osteoporosis in a Man With Low Testosterone: Replace the Hormone or Treat the Bone Directly
A single patient whose low testosterone and low bone density were found on the same workup. The disagreement is whether correcting the hormone is itself the bone treatment, or whether it's a parallel problem that doesn't substitute for one.
Desmond T., a 59-year-old man, has worked the overnight shift at a regional distribution center for over fifteen years, a schedule he says has quietly worn on him in ways he only started naming out loud after his wife pushed him to see someone about his low energy and flagging libido. The workup for those symptoms returned a low morning testosterone, confirmed on a second draw two weeks later at 218 and 231 ng/dL with an appropriately low LH — a pattern that puts the deficiency beyond a lab artifact and locates it centrally rather than in the testes.
What reframed the visit was something nobody had gone looking for. He had stepped off a loading-dock step some weeks earlier and cracked a rib, an event he took almost in stride at the time and which, in retrospect, was low-energy enough to prompt a DXA nobody had planned to order. It came back osteoporotic at −2.6 at the femoral neck — and read alongside a rib broken by a step off a dock, that number stops being a screening result and becomes confirmation that the fracture was a fragility event rather than bad luck. His hypogonadism and his bone loss surfaced at the same visit, which is part of why the group is now arguing about whether they are one problem or two. Testosterone does improve bone density in hypogonadal men; Snyder and colleagues' Bone Trial, within the Testosterone Trials, measured volumetric density and estimated strength and found real gains. But it measured density, not fractures — and where fractures have been counted, in the TRAVERSE fracture substudy, the testosterone arm accrued numerically more of them than placebo, not fewer. That is the distinction his rib turns into a live question rather than an academic one.
One hormone problem, or two problems that happen to overlap
His hypogonadism is confirmed on two separate morning draws, not borderline. Testosterone replacement has a real, demonstrated effect on bone density in hypogonadal men — Snyder and colleagues' Bone Trial, part of the Testosterone Trials, showed measurable gains in volumetric bone density and estimated bone strength. Treating the hormone deficiency addresses the actual driver rather than only managing the downstream bone loss.
I don't dispute the hypogonadism or that testosterone improves BMD in this population. What I'd flag is that the Bone Trial measured density, not fractures — and where fractures have actually been counted, the result cuts the other way. Snyder and colleagues' fracture substudy within TRAVERSE found numerically more clinical fractures in the testosterone arm than in placebo, not fewer. Set that against Orwoll and colleagues' work establishing alendronate's fracture reduction in men, and he's not a low-T-score-only patient anymore — he already has a fragility fracture.
Waiting to see whether correcting his testosterone improves his BMD enough on its own, before starting an agent with actual fracture-endpoint evidence, is a real delay for someone who's already broken a bone.
I don't think this needs to be either/or. His hypogonadism is real and worth treating on its own terms — fatigue, libido, quality of life — independent of what it's doing to his bones. Nothing about starting a bisphosphonate requires excluding testosterone, and nothing about starting testosterone should be used as a reason to delay a bisphosphonate given his existing fracture.
The honest uncertainty is how much of his future BMD trajectory either drug ends up driving individually — that's genuinely hard to disentangle once both are running — but that uncertainty isn't a reason to withhold the one therapy with demonstrated fracture protection while it gets sorted out.
Agreed: start alendronate now given his existing fracture, and begin testosterone replacement in parallel to address his confirmed hypogonadism directly rather than treating either drug as a substitute for the other.
Not fully settled: how the group will disentangle which therapy is driving his BMD trajectory at his follow-up DXA — a genuine limitation of running both together that nobody proposed a clean answer for, since separating the two wasn't judged worth delaying either one.